sb 203580 has been researched along with osu 03012 in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (osu 03012) | Trials (osu 03012) | Recent Studies (post-2010) (osu 03012) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 85 | 0 | 55 |
| Protein | Taxonomy | sb 203580 (IC50) | osu 03012 (IC50) |
|---|---|---|---|
| 3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bharate, SB; Raghuvanshi, R | 1 |
1 other study(ies) available for sb 203580 and osu 03012
| Article | Year |
|---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |